10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
Rhea-AI Summary
10x Genomics (Nasdaq: TXG) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 12, 2026. A public conference call and live webcast for analysts and investors begins at 1:30 p.m. PT / 4:30 p.m. ET to discuss results, business developments and outlook. The earnings news release will be posted on the company's website prior to the call. Interested parties can access a live webcast of the fireside chat on the Investors section at https://investors.10xgenomics.com/. The webcast will be archived for replay for at least 45 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – TXG
On the day this news was published, TXG declined 3.49%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TXG is up 2.86% while key peers show mixed moves: CERT +0.73%, OMCL +1.84%, SDGR +0.43% versus PHR -1.33% and GDRX -1.15%. With no peers in the momentum scanner and no same-day peer news, the reaction appears more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 15 | Reverse stock split | Neutral | +1.3% | Completed 1-for-5 reverse stock split for Amcor ordinary shares. |
| Jan 12 | Collaboration announcement | Positive | -3.2% | Launched 1,000-patient autoimmune blood-based single-cell diagnostic study. |
| Jan 12 | Collaboration announcement | Positive | -3.2% | Multi-year Dana-Farber collaboration on tumor single cell and spatial profiling. |
| Jan 12 | AI initiative | Positive | -3.2% | AI-driven immuno-oncology initiative using over 20,000 samples and 500M cells. |
| Dec 29 | Conference presentation | Positive | +0.9% | Planned presentation at 44th Annual J.P. Morgan Healthcare Conference. |
Recent TXG news tied to strategic collaborations showed negative price reactions despite constructive operational developments, while investor events and this Amcor corporate action showed modest positive alignment.
Recent disclosures for 10x Genomics highlight a mix of strategic, scientific, and corporate updates. On Nov 6, 2025, the company reported Q3 2025 revenue of $149.0 million and a $27.5 million net loss, alongside a year‑to‑date revenue base of $476.8 million and cash and securities of $482.1 million. Multiple collaborations announced on Jan 12, 2026 in autoimmune disease and tumor profiling, plus an AI-driven immuno-oncology initiative, all saw shares decline about 3.23%. An investor presentation announcement on Dec 29, 2025 drew a modestly positive reaction. Today’s earnings date notice follows preliminary Q4/FY 2025 figures already furnished in an 8-K on Jan 12, 2026.
Market Pulse Summary
This announcement sets the timeline for 10x Genomics’ Q4 and full-year 2025 results on February 12, 2026, following preliminary figures already furnished in an 8-K on January 12, 2026. The stock trades near its 52-week high and above the 200-day MA, reflecting prior expectations. Recent collaborations in autoimmune disease, oncology, and AI-driven immuno-oncology underscore strategic focus areas. When the results are released, investors will likely focus on revenue trends, margin dynamics, and updates to the company’s outlook and cash position.
AI-generated analysis. Not financial advice.
Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-12-2026-302667505.html
SOURCE 10x Genomics, Inc.
FAQ
When will 10x Genomics (TXG) report Q4 and full year 2025 results?
What time is the 10x Genomics (TXG) earnings call on February 12, 2026?
Where can I watch the 10x Genomics (TXG) Q4 2025 webcast?
Will 10x Genomics (TXG) publish the press release before the call on February 12, 2026?
How long will the 10x Genomics (TXG) webcast be available for replay?
